БЕК Штефан (CH),БРАХАТ Арндт (CH),ХЮБЕР Вольфганг (CH),ЛИ Яли (US),ВАН Ин (US),ЕЛЕНСКИЙ Роман (US)
申请号：
RU2014146594
公开号：
RU2014146594A
申请日:
2013.04.18
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method for the selective treatment of a patient having ankylosing spondylitis (AS), comprising selectively administering a therapeutically effective amount of an IL-17 antagonist to a patient based on the fact that said patient: a) has at least one treatment response AS allele selected from the responding allele in rs2201841 or the responding allele in rs11209032； or b) does not have at least one non-responsive AS allele selected from the non-responding allele in rs30187 or the non-responding allele in rs27434.2. A method for selectively treating a patient having AS using an IL-17 antagonist, comprising: a) selecting a patient for treatment with an IL-17 antagonist based on the fact that the patient: (i) has at least one allele that responds to treatment with AS, selected from the corresponding allele in rs2201841 or the corresponding allele in rs11209032； or (ii) does not have at least one non-responsive AS allele selected from a non-responding allele in rs30187 or a non-responding allele in rs27434； and b) thereafter, administering to the patient a therapeutically effective amount of an IL-17.3 antagonist. The method of claim 2, further comprising analyzing the biological sample from the patient for the presence or absence of at least one allele responding to AS treatment or at least one allele not responding to AS treatment, wherein the analysis step is carried out prior to screening step (a) .four. The method of claim 3, wherein the allele of the non-treatment AS or allele of the response to treatment AS is detected by analyzing a biological sample for the genomic sequence of the allele of the non-response AS or allele of the response to AS, the nucleotide product of the allele of the non-response AS treatment response allele AS, the polypeptide allele product does not respond1. Способ селективного лечения пациента, имеющего анкилозирующий спондилит (AS), включающий в себя селективное введение терапевтически эффективного количества антагониста IL-17 пациент
